Mylab, firm that makes kits to detect Covid, starts pathology test facility

"We are now getting to 'wet' pathology tests like blood tests etc and we have set up a centre which will have minimal human intervention and maximum automation

Mylab Discovery solutions
In February, Mylab said it is working on two or three technology platforms for Covid19 vaccines
Sohini Das Mumbai
2 min read Last Updated : Jul 28 2022 | 11:42 PM IST
Mylab Discovery Solutions, a biotech company backed by Serum Institute of India (SII), on Thursday started a pathology tests centre in Pune as it considers providing diagnostic services

The long-term plans include providing imaging solutions like X-ray, said Hasmukh Rawal, managing director of the Pune-based company, which is credited with developing India’s first indigenous Sars-CoV-2 RT-PCR and the first rapid-antigen home test kit.

 “We are now getting to ‘wet’ pathology tests like blood tests etc and we have set up a centre which will have minimal human intervention and maximum automation. The idea is to have the entire gamut of tests under the Mylab umbrella,” Rawal told 'Business Standard'.

Spread over 42,000 square feet, the pathology centre will have research capabilities for scientists and engineers. It will have more than 450 employees --70 per cent being research scientists. “It is the only centre in India that will develop and commercialize pioneering diagnostic innovations in diverse fields including molecular, serology, immunology, Automation, Robotics, AI based diagnostic solutions, devices and biosensors,” Mylab said.

Also Read: Serum Institute in talks with Danish firm to import monkeypox vaccine

“The Centre will pave the way for the development of new generation diagnostics that will address clinical unmet needs and increase patient access to quality diagnostics in the world,” said Cyrus Poonawalla, chairman and managing director of SII.

In February, Mylab said it is working on two or three technology platforms for Covid19 vaccines. Vaccine production would start at its partner Shilpa Biological’s Dharwad site in March. Mylab plans to start by making and marketing a Covid19 vaccine. The company plans to make biologic drugs too, and is currently working on a few molecules.

Earlier this month, Mylab launched the country’s first combined RT-PCR test kit for monsoon diseases. The test can detect and differentiate between malaria, Chikungunya, dengue, Zika, Leptospirosis and Salmonellosis bacterial species, and Leishmaniasis parasites. 

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusSerum Institute of IndiaCoronavirus TestsbiotechBiotechnologySerum InstitutecoronaVaccineDiagnostic

Next Story